You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 5, 2025

Patent: 9,067,992


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,067,992
Title:Use of TNF.alpha. inhibitor for treatment of psoriatic arthritis
Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF.alpha. antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF.alpha. antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
Inventor(s): Hoffman; Rebecca S. (Wilmette, IL), Weinberg; Mark (Northbrook, IL)
Assignee: AbbVie Biotechnology Ltd. (Hamilton, BM)
Application Number:14/563,056
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,067,992
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive Analysis of the Claims and Patent Landscape for United States Patent 9,067,992

Introduction

United States Patent 9,067,992, like any other patent, exists within a complex and evolving patent landscape. This analysis will delve into the specifics of the patent, the legal framework governing it, and the broader implications of such patents in the U.S. patent system.

Overview of the Patent

To begin, it is crucial to understand the specifics of the patent in question. However, since the exact details of Patent 9,067,992 are not provided, we will discuss the general principles and processes that apply to patents of this nature.

Patent Type and Subject Matter

Patents can be categorized into various types, including utility patents, design patents, and plant patents. Utility patents, which are the most common, cover new and useful processes, machines, manufactures, or compositions of matter, or any improvement thereof[3].

Business Method Patents

If Patent 9,067,992 falls under the category of business method patents, it would be subject to specific scrutiny. Business method patents, such as those challenged under the Covered Business Method (CBM) program, focus on ways of doing business in areas like banking or e-commerce. These patents have been a subject of controversy due to their potential impact on innovation and litigation costs[1].

Legal Framework and Challenges

The America Invents Act (AIA)

The 2011 Leahy-Smith America Invents Act (AIA) significantly altered the U.S. patent landscape. It introduced new administrative challenges to patent validity, including Inter Partes Review (IPR) and Post-Grant Review (PGR), which are heard by the Patent Trial and Appeal Board (PTAB)[2].

Patent Trial and Appeal Board (PTAB)

PTAB is a critical component in the challenge process. It decides on the validity of patents through IPR and PGR proceedings, which are generally faster and less expensive than federal court litigation. These proceedings require a lower burden of proof to invalidate patents, making them a preferred route for many accused infringers[2].

Covered Business Method (CBM) Review

The CBM program, specifically designed for business method patents, allows entities facing infringement lawsuits to challenge the validity of these patents. From September 2012 through September 2017, the CBM program saw 524 petitions filed, resulting in decisions against about one-third of the challenged patents. This program was set to expire in September 2020 but has been praised for reducing lawsuits involving business method patents[1].

Patentability Requirements

For a patent to be valid, it must meet several fundamental requirements:

Novelty

The claimed invention must be new and not previously disclosed in the prior art. If every element of the claimed invention is already disclosed, no valid patent can issue[2].

Nonobviousness

The invention must be nonobvious, meaning it must be significantly different from existing knowledge. This is determined by whether the invention would have been obvious to a person of ordinary skill in the relevant field[2].

Utility

The invention must be useful, meaning it must have a practical application. This requirement ensures that patents are granted only for inventions that serve a purpose[3].

Subject Matter Eligibility

The invention must be directed to eligible subject matter. This involves determining whether the patent claims are directed to a law of nature, natural phenomenon, or abstract idea, and if so, whether they contain an inventive concept that transforms the nature of the claim[2].

Challenges and Criticisms

Efficiency and Cost

Administrative challenges like IPR and PGR are often preferred due to their efficiency and lower costs compared to federal court litigation. However, these processes have also been criticized for making it too easy to challenge patents, potentially stifling innovation and creating uncertainty in patent rights[2].

Stakeholder Views

Stakeholders have mixed views on these programs. While many agree that they reduce unwarranted litigation costs and improve patent quality, others argue that they create uncertainty and discourage investments in patent-intensive industries[2].

Impact on Innovation and Litigation

Reducing Litigation Costs

Programs like CBM and IPR have been effective in reducing the number of lawsuits involving business method patents. By providing a faster and less expensive alternative to federal court litigation, these programs help in managing litigation costs and promoting more efficient dispute resolution[1].

Balancing Innovation and Protection

The patent system aims to balance the need to protect inventors' rights with the need to promote innovation. Overly broad or poorly defined patents can stifle innovation by limiting access to technology. Conversely, strong, well-defined patents can encourage innovation by providing clear incentives for inventors[2].

Best Practices and Guidance

USPTO Guidance

The U.S. Patent and Trademark Office (USPTO) has issued various guidance documents to ensure consistency and predictability in PTAB decisions. These include standard operating procedures for designating decisions as precedential or informative and processes for reviewing decisions for consistency[1].

Use of AI Tools

Recent guidance from the USPTO also addresses the use of AI tools in patent drafting. Practitioners must verify the accuracy of factual assertions and ensure that AI-generated documents do not introduce inaccurate statements or omit material information[5].

Key Takeaways

  • Patent Challenges: Administrative challenges like IPR, PGR, and CBM provide efficient and cost-effective alternatives to federal court litigation for challenging patent validity.
  • Patentability Requirements: Patents must meet novelty, nonobviousness, utility, and subject matter eligibility requirements to be valid.
  • Impact on Innovation: The patent system must balance protection of inventors' rights with the promotion of innovation, avoiding overly broad or poorly defined patents.
  • USPTO Guidance: Clear guidance from the USPTO is essential for ensuring consistency and predictability in PTAB decisions.
  • AI Tools: The use of AI tools in patent drafting requires careful verification to maintain accuracy and compliance with patent laws.

FAQs

What is the Covered Business Method (CBM) program?

The CBM program allows entities facing infringement lawsuits to challenge the validity of business method patents at the USPTO, providing a faster and less expensive alternative to federal court litigation[1].

How do IPR and PGR differ from CBM?

IPR and PGR are broader administrative challenges to patent validity, while CBM is specifically designed for business method patents. IPR and PGR can be used to challenge a wider range of patents, not just business methods[2].

What are the fundamental requirements for patentability?

The fundamental requirements include novelty, nonobviousness, utility, and subject matter eligibility. These ensure that only valid and useful inventions are patented[2].

How has the AIA impacted the U.S. patent landscape?

The AIA introduced new administrative challenges like IPR and PGR, and created PTAB to hear these challenges. This has significantly altered how patents are challenged and validated, aiming to improve patent quality and reduce litigation costs[2].

What are the implications of using AI tools in patent drafting?

Using AI tools in patent drafting requires careful verification to ensure accuracy and compliance with patent laws. Practitioners must ensure that AI-generated documents do not introduce inaccurate statements or omit material information[5].

Sources

  1. GAO Report: Assessment of the Covered Business Method Patent Review Program, March 2018.
  2. Congressional Research Service: The Patent Trial and Appeal Board and Inter Partes Review, Updated May 28, 2024.
  3. Chisum on Patents: LexisNexis Store, Donald S. Chisum's authoritative analysis of patent law.
  4. Office of Inspector General: USPTO Should Strengthen Its Planning and Oversight of Patent Data Capture Contracts, August 16, 2022.
  5. BIPC: U.S. Patent Office Issues Additional Guidance on Use of AI Tools, April 15, 2024.

More… ↓

⤷  Subscribe

Details for Patent 9,067,992

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Abbvie Inc. HUMIRA adalimumab Injection 125057 December 31, 2002 ⤷  Subscribe 2021-03-07
Abbvie Inc. HUMIRA adalimumab Injection 125057 February 21, 2008 ⤷  Subscribe 2021-03-07
Abbvie Inc. HUMIRA adalimumab Injection 125057 April 24, 2013 ⤷  Subscribe 2021-03-07
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.